A new study may help clinicians balance the risks and potential benefits of suspending natalizumab dosing in patients with relapsing multiple sclerosis (MS), according to research presented here at the 135th Annual Meeting of the American Neurological Association (ANA).
There is no clear answer, said Timothy West, MD, University of California San Francisco (UCSF) Multiple Sclerosis Center, San Francisco, California, on September 15. Continuing dosing appears to increase the risk for developing progressive multifocal leucoencephalopathy (PML). Suspending dosing to reduce the risk of PML may contribute to an increased risk for MS flares.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1768